Siddharthan Chandran

Prof Siddharthan Chandran

Director & CEO

Dissecting a genetic cause of ALS and FTD and identifying ways to help protect neurons

Condition

Motor neuron disease/ALS, Frontotemporal dementia

Biography

Professor Siddharthan Chandran is Director of the UK Dementia Research Institute, and an internationally leading expert in neurodegenerative diseases. Prof Chandran is a practising neurologist and scientist working at the forefront of the emerging discipline of Regenerative Neurology, renowned for his work in motor neuron disease (MND) and MS that combines laboratory and clinical research with a particular focus on human / patient stem cells for his discovery science research. Alongside his UK DRI research, Prof Chandran is Director of the Euan MacDonald Centre for Motor Neuron Disease Research and the Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh. He is also a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences.

News

Key publications

Acta Neuropathol
Published
PolyGA targets the ER stress-adaptive response by impairing GRP75 function at the MAM in C9ORF72-ALS/FTD.
Authors
Federica Pilotto, Alexander Schmitz, Niran Maharjan, Rim Diab, Adolfo Odriozola, Priyanka Tripathi, Alfred Yamoah, Olivier Scheidegger, Angelina Oestmann, Cassandra N Dennys, Shrestha Sinha Ray, Rochelle Rodrigo, Stephen Kolb, Eleonora Aronica, Stefano Di Santo, Hans Rudolf Widmer, Nicolas Charlet-Berguerand, Bhuvaneish T Selvaraj, Siddharthan Chandran, Kathrin Meyer, Benoît Zuber, Anand Goswami, Joachim Weis, Smita Saxena
PolyGA targets the ER stress-adaptive response by impairing GRP75 function at the MAM in C9ORF72-ALS/FTD.
BMJ Open
Published
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Authors
Charis Wong, Rachel S Dakin, Jill Williamson, Judith Newton, Michelle Steven, Shuna Colville, Maria Stavrou, Jenna M Gregory, Elizabeth Elliott, Arpan R Mehta, Jeremy Chataway, Robert J Swingler, Richard Anthony Parker, Christopher J Weir, Nigel Stallard, Mahesh K B Parmar, Malcolm R Macleod, Suvankar Pal, Siddharthan Chandran
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Nat Commun
Published
Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology.
Authors
Zoeb Jiwaji, Sachin S Tiwari, Rolando X Avilés-Reyes, Monique Hooley, David Hampton, Megan Torvell, Delinda A Johnson, Jamie McQueen, Paul Baxter, Kayalvizhi Sabari-Sankar, Jing Qiu, Xin He, Jill Fowler, James Febery, Jenna Gregory, Jamie Rose, Jane Tulloch, Jamie Loan, David Story, Karina McDade, Amy M Smith, Peta Greer, Matthew Ball, Peter C Kind, Paul M Matthews, Colin Smith, Owen Dando, Tara L Spires-Jones, Jeffrey A Johnson, Siddharthan Chandran, Giles E Hardingham
Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology.

Chandran Lab

Explore the work of the Chandran Lab, Dissecting a genetic cause of ALS and FTD and identifying ways to help protect neurons.

 
Chandran Lab
Human stem cell-derived myelinating oligodendrocyte can be seen with many myelinating processes wrapped around unstained neurons